Kittleson Michelle M
, 8536 Wilshire Boulevard, Suite 301, Beverly Hills, CA, 90211, USA,
Curr Treat Options Cardiovasc Med. 2012 Aug;14(4):356-69. doi: 10.1007/s11936-012-0184-7.
Heart transplantation is the preferred therapy for patients with end-stage heart failure with refractory symptoms despite optimal medical and device therapy. The major impediment to survival is rejection and infection in the short term and cardiac allograft vasculopathy and malignancy in the long term. Current therapies are focused on the prevention and treatment of rejection and limiting the long-term problems of cardiac allograft vasculopathy and malignancy. Advances in monitoring assays now allow better assessment of rejection and the level of immune response. This will allow clinicians, in the future, to tailor current therapies to the needs of individual heart transplant recipients to maximize benefit and minimize toxicity.
心脏移植是终末期心力衰竭患者的首选治疗方法，尽管进行了最佳的药物和器械治疗，但这些患者仍有难治性症状。短期内存活的主要障碍是排斥反应和感染，长期则是心脏移植血管病变和恶性肿瘤。目前的治疗方法主要集中在预防和治疗排斥反应以及限制心脏移植血管病变和恶性肿瘤的长期问题。监测检测方法的进展现在能够更好地评估排斥反应和免疫反应水平。这将使临床医生在未来能够根据个体心脏移植受者的需求调整当前治疗方法，以实现效益最大化和毒性最小化。
